6 results
To determine the value of quantitative whole body PET with [18F]PEG-Folate to predict development of clinical arthritis within one year follow-up in arthralgia patients with a positive autoantibody ACPA test.
2 Objectives2.1 Primary objective •To evaluate FAZA-PET/CT as a prognostic factor of the loco-regional control rate at 2 years in HNSCC patients receiving chemo-radiotherapy ± nimorazole.•Time to locoregional recurrence is counted from the day of…
Primary Objective: to evaluate arterial [18F]fluor-PEG-folate uptake on PET/CT in patients with active, large vessel GCA; and in the same patients after 9 months of standard treatment.Secondary objectives are:- Assessment of the relationship between…
The primary objective is to estimate the average relative change from baseline in tumoruptake of [89Zr]Zr-BI 765063 (arm A) or [89Zr]Zr-BI 770371 (arm B) upon treatment with BI 765063 (arm A) or BI 770371 (arm B).
To investigate the maximum tolerated dose (MTD) of BI 907828 in combination with ezabenlimab based on dose limiting toxicities (DLT) during the first treatment cycle and the recommended dose for expansion (RDE), safety and tolerability,…
To investigate the association between quantitative changes in whole body F-18-PEG Folate PET/CT (Folate PET) after 4 weeks and clinical response to anti-TNF therapy at 26 weeks of treatment in patients with clinically active established RA.